Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Extension of indication recommended for Arixtra, Quixidar

Aug. 3, 2004

GSK researchers design novel thrombin/factor Xa inhibitors

July 30, 2004

New factor VIIa/TF inhibitors under study at Schering AG

July 30, 2004

Potent and selective FXa inhibitors reported by Pfizer

July 27, 2004

Mandelic acid derivatives claimed for inhibiting coagulation factors

July 16, 2004

Bayer extends support for study in prophylactic treatment of hemophilia A

July 15, 2004

Nuvelo closes phase II alfimeprase study early

July 15, 2004

Factor Xa and VIIa inhibitors reported by Merck KGaA

July 12, 2004

Nuvelo reports preliminary data from phase II study of alfimeprase in PAO

July 7, 2004

Centocor and Fujisawa discontinue codevelopment of abciximab in Japan

July 6, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...